Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Published on 23/03/2025 at 23:00

S&P Capital IQ

-3.66%

Bolt Biotherapeutics, Inc. filed its 10-K on Mar 24, 2025 for the period ending Dec 31, 2024. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Announces 120 Reverse Stock Split Effective June 6, 2025	06-06	RE
Bolt Biotherapeutics, Inc. - Special Call	05-12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs Targeting Cea and PD-L1 At AACR Annual Meeting 2025	04-30	CI
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 At AACR Annual Meeting 2025	04-25	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	03-24	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	03-24	CI
Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	03-23	CI
Aadi Bioscience Appoints David Dornan, Phd, as Chief Scientific Officer	02-18	CI
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc	02-11	CI
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024	12-23	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-12	CI
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting	11-07	CI
Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors	04/09/24	CI
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	13/08/24	CI
Bolt Biotherapeutics, Inc. Announces Management Changes	20/05/24	CI
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	20/05/24	CI
Top Midday Decliners	15/05/24	MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05/24	MT
Top Premarket Decliners	15/05/24	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15/05/24	MT
Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	15/05/24	MT
Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05/24	MT
HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	15/05/24	MT
Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	15/05/24	MT